Hepatitis C And Hepatocarcinoma: Response And Treatment | 3512
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 1337

Journal of Gastrointestinal & Digestive System received 1337 citations as per google scholar report

Journal of Gastrointestinal & Digestive System peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Hepatitis C and hepatocarcinoma: Response and treatment

2nd International Conference on Gastroenterology & Urology

Ahmed A. Abd-Rabou

AcceptedAbstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X.S1.019

Background: Liver disease is a general term for any damage that reduces the functioning of the liver. The prevalence of hepatitis C virus (HCV) infection varies across the world, with the highest number reported in Egypt. HCV infects liver and may lead to hepatocellular carcinoma (HCC). Objectives: The assessment of new strategies for response and treatment of HCV and HCC is the broad objective of this work. Material & Methods: Quantification of HCV-RNA by qRT-PCR was performed for every patient. Gene polymorphisms of Bcl-2 (Ala43Thr) using PCR-RFLP and GH levels using ELISA were tested. On the other hand, infected Huh-7 cells were transfected with the SiRNAs targeting the viral genome. Results: HCV patients have high significant differences of Bcl-2 43Thr genotype and GH levels when comparing non-responders with responders. There were high significant differences, in the levels of cell density, γ-IFN, CD4, and CD8, when comparing control cultured cells with curcumin and taurine treated cultured cells. Conclusions: We concluded that Bcl-2 gene and GH levels can be used as sensitive biomarkers for HCV response to IFN therapy and suggested that curcumin and taurine can be used in combination with standard therapeutic lines for hepatoma treatment.